Cyclo Historical Income Statement
| CYTH Stock | USD 0.72 0.04 5.88% |
Historical analysis of Cyclo Therapeutics income statement accounts such as Interest Expense of 181.7 K, Total Revenue of 995.2 K or Other Operating Expenses of 22.2 M can show how well Cyclo Therapeutics performed in making a profits. Evaluating Cyclo Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cyclo Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cyclo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cyclo Therapeutics is a good buy for the upcoming year.
Cyclo |
About Cyclo Income Statement Analysis
Cyclo Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cyclo Therapeutics shareholders. The income statement also shows Cyclo investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cyclo Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Cyclo Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cyclo Therapeutics. It is also known as Cyclo Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Cyclo Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cyclo Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Cost Of Revenue
Cost of Revenue is found on Cyclo Therapeutics income statement and represents the costs associated with goods and services Cyclo Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Cyclo Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Total Operating Expenses is increasing as compared to previous years. The Cyclo Therapeutics' current Selling And Marketing Expenses is estimated to increase to 7,002, while Depreciation And Amortization is projected to decrease to under 18.3 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 15.7M | 16.8M | 17.6M | 18.5M | Cost Of Revenue | 156.1K | 138.9K | 3.5M | 3.7M |
Cyclo Therapeutics income statement Correlations
Click cells to compare fundamentals
Cyclo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclo Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 147.4K | 12.8K | 16.8K | 19.5K | 19.3K | 18.3K | |
| Total Revenue | 1.0M | 903.4K | 1.6M | 1.4M | 1.1M | 995.2K | |
| Gross Profit | 931.7K | 837.0K | 1.4M | 1.2M | (2.4M) | (2.3M) | |
| Other Operating Expenses | 8.4M | 9.9M | 15.9M | 17.0M | 21.1M | 22.2M | |
| Operating Income | (7.4M) | (9.0M) | (14.3M) | (15.6M) | (20.1M) | (19.0M) | |
| Ebit | (7.4M) | (9.0M) | (14.3M) | (15.6M) | (20.1M) | (19.0M) | |
| Ebitda | (7.2M) | (8.9M) | (14.3M) | (15.6M) | (20.0M) | (19.0M) | |
| Cost Of Revenue | 75.5K | 66.4K | 156.1K | 138.9K | 3.5M | 3.7M | |
| Total Operating Expenses | 8.3M | 9.8M | 15.7M | 16.8M | 17.6M | 18.5M | |
| Income Before Tax | (7.5M) | (8.9M) | (14.3M) | (15.5M) | (20.1M) | (19.1M) | |
| Total Other Income Expense Net | (141.7K) | 19.8K | 3.4K | 171.0K | (7.2K) | (7.6K) | |
| Net Income | (7.7M) | (8.9M) | (14.3M) | (15.3M) | (20.1M) | (19.1M) | |
| Income Tax Expense | 141.7K | (18.5K) | 18.5K | (171.0K) | 4.0 | 3.8 | |
| Selling General Administrative | 3.4M | 3.7M | 6.5M | 7.8M | 5.7M | 2.9M | |
| Selling And Marketing Expenses | 5.9K | 5.0K | 18.3K | 13.1K | 3.9K | 7.0K | |
| Research Development | 4.9M | 6.1M | 9.2M | 9.0M | 14.2M | 14.9M | |
| Net Income From Continuing Ops | (7.5M) | (8.9M) | (14.3M) | (15.5M) | (19.4M) | (18.4M) | |
| Net Income Applicable To Common Shares | (7.5M) | (8.9M) | (14.3M) | (15.5M) | (13.9M) | (13.2M) | |
| Reconciled Depreciation | 5.7K | 12.8K | 16.8K | 19.5K | 19.3K | 14.7K |
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.